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Abstract
 
Recent studies in transgenic mice have revealed that expression of a dominant negative form of
the transcription factor GATA-3 in T cells can prevent T helper cell type 2 (Th2)-mediated al-
lergic airway inflammation in mice. However, it remains unclear whether GATA-3 plays a role
in the effector phase of allergic airway inflammation and whether antagonizing the expression
and/or function of GATA-3 can be used for the therapy of allergic airway inflammation and
hyperresponsiveness. Here, we analyzed the effects of locally antagonizing GATA-3 function in
a murine model of asthma. We could suppress GATA-3 expression in interleukin (IL)-4–pro-
ducing T cells in vitro and in vivo by an antisense phosphorothioate oligonucleotide overlap-
ping the translation start site of GATA-3, whereas nonsense control oligonucleotides were vir-
tually inactive. In a murine model of asthma associated with allergic pulmonary inflammation
and hyperresponsiveness in ovalbumin (OVA)-sensitized mice, local intranasal administration of
fluorescein isothiocyanate–labeled GATA-3 antisense oligonucleotides led to DNA uptake in
lung cells associated with a reduction of intracellular GATA-3 expression. Such intrapulmonary
blockade of GATA-3 expression caused an abrogation of signs of lung inflammation including
infiltration of eosinophils and Th2 cytokine production. Furthermore, treatment with antisense
but not nonsense oligonucleotides induced a significant reduction of airway hyperresponsive-
ness in OVA-sensitized mice to levels comparable to saline-treated control mice, as assessed by
both enhanced pause (PenH) responses and pulmonary resistance determined by body plethys-
mography. These data indicate a critical role for GATA-3 in the effector phase of a murine
asthma model and suggest that local delivery of GATA-3 antisense oligonucleotides may be a
novel approach for the treatment of airway hyperresponsiveness such as in asthma. This ap-
proach has the potential advantage of suppressing the expression of various proinflammatory
Th2 cytokines simultaneously rather than suppressing the activity of a single cytokine.
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Introduction
 
Allergic asthma is a chronic pulmonary disease associated
with bronchoconstriction and chronic inflammation of the
airways (1–3). In allergic asthma, there is a polarization of T
lymphocyte responses and enhanced secretion of cytokines
involved in regulation of IgE, mast cells, basophils, and eosi-
nophils, ultimately leading to inflammation and disease (4).
The proinflammatory cytokines produced by T cells con-
tribute to the initiation and perpetuation of allergic asthma
(1–3). In particular, it has been shown that allergic airway
inflammation in patients with asthma and animal models of
allergic airway inflammation is associated with increased
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Th2 (IL-4, IL-5, IL-13) cytokine production (5–8). In this
regard, IL-4 has been postulated to be critical for the devel-
opment of Th2 T cells in asthmatic airways and the reduced
expression of the IL-12 receptor 
 
 
 
2 chain on lung Th1 cells
(6, 9, 10). Furthermore, it is believed to induce IgE isotype
switching in B cells in asthma and promotes goblet cell
metaplasia, mucus hypersecretion, and the recruitment of
eosinophils by upregulating vascular cell adhesion molecule
1 expression in pulmonary endothelial cells (10). The im-
portance of IL-4 is also underlined by the observation that
inhalation of IL-4 causes the development of sputum eosin-
ophilia and increased responsiveness of the airways and the
finding that neutralizing antibodies to IL-4 are therapeuti-
cally effective for asthma (1, 11, 12).
GATA-3 is a pleiotropic transcription factor of the C4
zinc finger family expressed in T cells, mast cells, eosino-
phils, basophils, and embryonic brain and kidney that binds
to a 5
 
 
 
-WGATAR-3
 
 
 
 consensus DNA sequence (13–16).
GATA-3 has been shown to be essential for the develop-
ment of the earliest T cell progenitor cells (17). Further-
more, GATA-3 was found to be selectively expressed in
Th2 but not in Th1 cells and to play an important role in
cytokine gene expression in T cells (18–21). In particular,
GATA-3 is important for the expression of IL-5 in T cells
by transactivation of the IL-5 promoter together with Ets-1
and Ets-2 proteins (20, 21). Furthermore, GATA-3 weakly
transactivates the IL-4 promoter in T cells (22). These
functions of GATA-3 on Th2 cytokine gene promoters
can be suppressed by repressor of GATA (ROG), a re-
cently cloned lymphoid-specific repressor of GATA-3–
induced transactivation (23). Finally, ectopic expression of
GATA-3 in developing Th1 cells leads to upregulation of
IL-4 and IL-5 and downregulation of IFN-
 
 
 
. The latter ef-
fect appears to be partly due to downregulation of the IL-
12 receptor 
 
 
 
2 chain (18, 19, 24).
Activation studies in retroviral infected T cells have
shown that the activation of GATA-3 in T cells occurs upon
activation of the IL-4/signal transducer and activator of tran-
scription (STAT)
 
1
 
-6 signaling pathway (25), suggesting that
the exposure of naive T cells to IL-4 may be a very early
event that induces GATA-3 activation and Th2 cell differ-
entiation. However, GATA-3 can fully reconstitute Th2
development in STAT-6–deficient T cells, suggesting that it
is a master switch both in STAT-6–dependent and –inde-
pendent Th2 development (26). Finally, GATA-3 has been
shown to exert STAT-6–independent autoactivation, creat-
ing a feedback pathway stabilizing Th2 commitment (26).
Based on the above data, it was of particular interest to
analyze the expression and functional role of GATA-3 in
patients with atopic asthma. Indeed, in a recent study Na-
kamura and co-workers (27) showed an increased expres-
 
sion of GATA-3 mRNA in asthmatic airways, suggesting
that GATA-3 may be involved in the regulation of Th2
cytokine responses in asthma. Based on this observation,
we analyzed in the present study the role of GATA-3 in a
mouse model of asthma (28) using an antisense DNA strat-
egy. We observed increased local production of GATA-3
in this model and demonstrate that local treatment with
GATA-3 antisense oligonucleotides could be successfully
used to downregulate Th2-induced pulmonary inflamma-
tion and airway hyperresponsiveness.
 
Materials and Methods
 
Reagents.
 
The following reagents were used: water-soluble
dexamethasone (DEX) and aluminum potassium sulfate (alum;
Sigma-Aldrich); crystalline OVA (Pierce Chemical Co.); biotiny-
lated monoclonal anti–mouse IL-4 (BD PharMingen), mono-
clonal and polyclonal goat antibody anti–GATA-3, (Santa Cruz
Biotechnology, Inc.) and monoclonal antiactin (Santa Cruz Bio-
technology, Inc.); horseradish peroxidase–conjugated anti–rabbit
Ig and anti–mouse Ig (Amersham Pharmacia Biotech), the ECL
Western blotting system (Amersham Pharmacia Biotech); bio-
tinylated anti–goat IgG (Vector Laboratories); Cy3/AMCA
Streptavidin conjugated (Dianova); and phosphorothioate oligo-
nucleotides (Roth GmbH and GIBCO BRL).
 
Phosphorothioate Oligonucleotides.
 
Oligonucleotides were syn-
thesized with a phosphorothioate backbone to improve resistance
to endonucleases. The antisense oligonucleotides consisted of 18-
mer analogues to the 5
 
 
 
 end of the murine GATA-3 sequence
which spans the translation initiation site. This sequence had no
C plus G dinucleotide or a quadruple G sequence element that
are known to cause unspecific effects. In addition, several control
(mismatched and nonsense) oligonucleotides were prepared. The
nonsense oligonucleotides contained the same nucleotide compo-
sition as the antisense oligonucleotides.
The sequences were as follows (mismatches are underlined):
GATA-3 antisense DNA (with or without FITC), 5
 
 
 
-AGT CAC
CTC CAT GTC CTC-3
 
 
 
; GATA-3 nonsense DNA, 5
 
 
 
-CTA
TGT CAT CCG CTC CAC-3
 
 
 
; GATA-3 mismatched DNA,
5
 
 
 
-AGC CAC CTA CAT TTC CTA-3
 
 
 
; and GATA-3 mis-
matched DNA 2, 5
 
 
 
-AGC CAC CTA GGC ATC CTC-3
 
 
 
.
 
Coincubation of DNA with Murine Spleen CD4
 
 
 
 Th2 Cells.
 
Naive splenic CD4
 
 
 
 T cells (purity
 
  
 
 97%) were obtained using
monoclonal antibodies to CD4 coupled to magnetic beads
(Miltenyi Biotec) according to the protocol provided by the
manufacturer. Cells were cultured on 10 
 
 
 
g/ml anti-CD3–
coated wells in the presence of 2 
 
 
 
g/ml anti-CD28, 100 U/ml
rmIL-2, and 1,000 U/ml rmIL-4 for 3 d. Cells were then cul-
tured for an additional 2 d in the presence of rmIL-2 and IL-4
only. During the last 12 h cells were challenged with 50 ng/ml
PMA and 1 
 
 
 
g/ml ionomycin. For coincubation experiments
phosphorothioate oligonucleotides (12–15 
 
 
 
M) were preincu-
bated for 45 min with Lipofectamine (Life Technologies/GIBCO
BRL). At days 2 and 4 the oligonucleotides were added to the
cell cultures. Cells treated with FITC-conjugated antisense DNA
were washed, fixed in 4% paraformaldehyde, and analyzed by
FACS
 
®
 
 analysis for uptake efficiency. Cell viability was assessed
by trypan blue staining and supernatants were analyzed for IL-4
and IL-9 production by ELISA.
 
Enrichment of Antisense-transfected Cells by Immunomagnetic Cell
Sorting.
 
To enrich for antisense-transfected T cells, T cells were
cotransfected on day 4 with the pMACS K
 
k
 
.II vector (Miltenyi
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchioalveolar lavage; BALF, BAL
fluid; DEX, dexamethasone; EMSA, electrophoretic mobility shift assay;
HPF, high power field; MACS, magnetic cell sorting; MCh, methacho-
line; PAS, periodic acid-Schiff; PenH, enhanced pause; RL, pulmonary
resistance; STAT, signal transducer and activator of transcription. 
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Biotec) expressing a truncated H2-K
 
k
 
 molecule (that is not ex-
pressed in BALB/c mice) and FITC-labeled or unlabeled phos-
phorothioate oligonucleotides. Cells were harvested 48 h after
cotransfection, resuspended in PBE (PBS with 5 mM EDTA)
buffer, and incubated with MACSelect K
 
k
 
 microbeads (Miltenyi
Biotec) followed by magnetic separation. FITC-positive cells
were visualized by fluorescence microscopy or confocal laser mi-
croscopy using a Bio-Rad Laboratories MRC-1024/MP micro-
scope. To assess enrichment of antisense-transfected cells, T cell
nuclei were counterstained with DAPI (Vector Laboratories) and
the percentage of FITC-positive cells was determined by count-
ing 12 randomly selected high power fields (HPFs) in three sam-
ples per condition by fluorescence microscopy. Cytokine produc-
tion in magnetic cell sorting (MACS)-selected T cells was assessed
after 18 h stimulation with 50 ng/ml PMA plus 1 
 
 
 
g/ml iono-
mycin by ELISA.
 
Allergen Sensitization/Challenge Protocol.
 
Female BALB/c
mice (6–8 wk of age) received an intraperitoneal injection of 100
 
 
 
g/ml OVA (0.2 ml of 500 
 
 
 
g/ml in normal saline) complexed
with alum on days 0 and 14. On days 25, 26, and 27, the mice
underwent anesthesia with 0.2 ml of avertine intraperitoneally (1
mg/ml of tryplomethan in amylalcohol; 2.5% in PBS) before re-
ceiving 50 
 
 
 
g OVA in saline intranasally. Control animals re-
ceived saline intraperitoneally with alum on days 0 and 14 and 50
 
 
 
l of saline intravenously on days 25, 26, and 27.
 
Antisense GATA-3 or DEX Treatment in OVA-sensitized
Mice.
 
To assess the effect of antisense GATA-3 treatment in air-
way inflammation, antisense or control oligonucleotides were
given by intranasal administration (200 
 
 
 
g/treatment) at days 24,
25, 26, and 27 (30 min before intravenous injection of OVA) to
OVA-sensitized mice. To localize antisense oligonucleotides in
vivo, we performed the last intranasal administration with FITC-
labeled antisense oligonucleotides.
To compare the efficiency of antisense GATA-3 treatment to
the classical treatment with glucocorticoids, a group of OVA-
treated mice was given 1 mg (50 
 
 
 
l vol) of water soluble DEX
intravenously in saline on days 24, 25, 26, and 27.
 
Collection and Analysis of Bronchioalveolar Lavage Fluid, Cytospins,
and ELISA for IFN-
 
 
 
 and IL-4.
 
24 h after the last intranasal
challenge with either OVA or saline at day 27, bronchioalveolar
lavage (BAL) of the right lung was performed after tying off the
left lung at the mainstem bronchus. Total BAL fluid (BALF; 1 ml
of saline three times) was collected and cells were counted using a
100-
 
 
 
l aliquot. Samples were centrifuged at 1,200 rpm for 5 min
at 4
 
 
 
C, and cell pellets were resuspended in PBS. Cytospins were
made by centrifugation at 450 rpm for 5 min at room tempera-
ture. Eosinophils were detected by staining according to May-
Grünwald Giemsa and subsequently analyzed with a ZEISS mi-
croscope at 400
 
 
 
.
To determine cytokine concentrations in BALF, samples were
centrifuged at 1,200 rpm for 5 min at 4
 
 
 
C. Supernatants were an-
alyzed by specific ELISA for content of IFN-
 
 
 
 and IL-4 using
commercially available kit systems (BD PharMingen).
 
Lung Histology.
 
24 h after the last intranasal challenge with ei-
ther OVA or saline, lungs were analyzed by histology (day 28).
The right lung was frozen immediately and stored in liquid nitro-
gen until use. The left lung was fixed in 10% formaline, dehy-
drated, mounted in paraffin, sectioned, and stained with hema-
toxylin/eosin. Eosinophils in the lungs were quantified blindly by
the same pathologist (H.A. Lehr) using a Leitz D33 microscope, a
JVC1 chip camera, the program Photoshop
 
®
 
, and an Image Pro-
cessing Tool Kit (v2.1). Three HPFs in the area of peripheral
 
bronchi were randomly selected for quantification. Counts are
given as eosinophils per square millimeter.
Airway mucus was identified by the alcian blue/periodic acid-
Schiff (PAS) reaction by using a standard protocol in use in our
Department of Pathology. PAS-positive mucosubstances in the
small and large airways were also assessed by semiquantitative
analysis in four to five mice per group using the following grading
scale: 
 
 
 
, no mucosubstances; 
 
 
 
, mucosubstances detectable;
 
  
 
, high amount of mucosubstances.
 
Immunohistochemistry.
 
Immunohistochemistry was performed
as described previously (29–31). In brief, frozen sections were
fixed in 4% paraformaldehyde and immunostained for GATA-3
and IL-4. In brief, sections were preincubated with 2% normal
rabbit serum in PBS/1% BSA/0.4% saponin for 45 min followed
by an incubation with anti–GATA-3 goat polyclonal antibodies
(5 
 
 
 
g/ml) in PBS/1% BSA/0.4% saponion/2% normal rabbit se-
rum overnight at 4
 
 
 
C. The next day sections were incubated with
biotinylated rabbit anti–goat IgG (1:100 dilution) followed by
Streptavidin-Cy3 (1:1,000 dilution).
For IL-4 staining studies, sections were then incubated over-
night with an anti–IL-4 biotinylated antibody (10 
 
 
 
g/ml; BD
PharMingen) in PBS/1% BSA/0.4% saponin followed by the
Streptavidin–conjugated Cy3 complex (1:1,000 in PBS). Sections
were analyzed with an Olympus fluorescence microscope.
 
Morphometric Analysis.
 
GATA-3– and IL-4–positive cells in
the lungs were quantified blindly by the same pathologist using an
Olympus microscope and an Image Processing Tool Kit (v2.1).
10 HPFs in the area of peripheral bronchi were randomly selected
in 4–5 mice per group for quantification. Counts are given as
positive cells per HPF.
 
Protein Analysis.
 
Lung tissues were homogenized by using an
electrical homogeneizator, and proteins were extracted in PBS in
the presence of protease inhibitors (6.75% aprotinin, 312 
 
 
 
g/ml
trypsin inhibitor) and 0.62% NP-40. Protein concentrations were
determined by a protein assay according to the manufacturer’s in-
structions (Bio-Rad Laboratories). The standard curve was per-
formed by using 0, 4, 8, and 16 
 
 
 
g of BSA per milliliter. Under
our experimental conditions
 
 
 
 
 
4 mg of proteins per lung could be
recovered.
 
Western Blot Analysis.
 
50 
 
 
 
g of total proteins isolated from
the whole lung was separated by 15% SDS-PAGE and blotted
onto a nitrocellulose membrane overnight (31). Equal loading
was assessed with Ponceau’s solution (Sigma-Aldrich). The mem-
brane was then incubated in blocking solution (5% dry milk in
PBS/0.05% Tween 20) for 1 h at room temperature, and subse-
quently exposed to 0.8 
 
 
 
g/ml of monoclonal antibodies anti–
GATA-3 or anti–
 
 
 
-actin overnight at 4
 
 
 
C. The day after, the
membrane was incubated with peroxidase-conjugated anti–
mouse Igs (1:2,500) for 1 h at room temperature. Finally, enzyme
activity was detected with the ECL-Plus Western blotting detec-
tion system according to the manufacturer’s instructions (Amer-
sham Pharmacia Biotech).
 
Electrophoretic Mobility Shift Assay.
 
Electrophoretic mobility
shift assay (EMSA) was carried out by the addition of 25,000 cpm
radiolabeled GATA-3, OCT-1, and SP1 consensus DNA probes
(Santa Cruz Biotechnology, Inc.) to the binding reaction that also
contained 1 
 
 
 
g synthetic DNA duplex of poly(dIdC), 30 
 
 
 
g of
total lung proteins, and binding buffer (32). Complex formation
was allowed to proceed for 30 min. Finally, the complexes were
separated from unbound DNA by native PAGE on 5% gels. The
GATA-3 bands on the EMSA gels were analyzed by densitome-
try as specified in Results. For supershift analysis, 1 
 
 
 
g GATA- 
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3–specific antibodies and control antibodies (obtained from Santa
Cruz Biotechnology, Inc.) were used as specified in Results.
 
Assessment of Airway Reactivity by Body Plethysmography.
 
Air-
way reactivity was assessed in 12 mice per group by head-out ple-
thysmography as described previously (33). In brief, mice were
placed in four body plethysmographs attached to an exposure
chamber (Crown Glass). Airflow was measured with a PTM 378/
1.2 pneumotachograph (Hugo Sachs Electronics) and an 8-T2
Figure 1. Suppression of IL-4 production and GATA-3 expression in Th2 T cells by a specific phosphorothioate oligonucleotide to the translation start
site of GATA-3. To induce Th2 T cell development naive splenic CD4  T cells (purity   97%) were cultured on anti-CD3–coated wells in the presence
of soluble anti-CD28, rmIL-2, and rmIL-4 for 3 d. Cells were then cultured for an additional 2 d in the presence of rmIL-2 and IL-4 only. During the last
12 h, cells were challenged with PMA (50 ng/ml)/ionomycin (1  g/ml). At days 2 and 4, oligonucleotides were preincubated with Lipofectamine and
added to the cell cultures as indicated. In vitro–differentiated Th2 cells showed high viability under all experimental conditions (UN, 85–95%; ASGATA3,
90–98%; NSGATA3, 75–95%) in three independent experiments as assessed by trypan blue exclusion (data not shown). Coincubation with FITC-labeled
antisense oligonucleotides to GATA-3 led to a high degree of DNA uptake (50–70% of cells) as assessed by FACS® analysis (A) and quantitative fluores-
cence microscopy using nuclear counterstaining with DAPI (B). Antisense oligonucleotides to GATA-3 led to a significant (P   0.05) reduction of the
number of GATA-3–expressing Th2 cells, whereas control nonsense oligonucleotides had no such effect (C). In addition, mismatched oligonucleotides
led to a reduction in the number of GATA-3–expressing cells, although this effect was not statistically significant. Cytokine production from untreated and
GATA-3 antisense or control-treated cells was assessed by ELISA. The treatment with antisense DNA to GATA-3 significantly (P   0.05) reduced IL-4
production (D) compared with untreated cells but, in contrast, IL-9 release remained unaffected after antisense GATA-3 treatment (E). In addition, con-
trol oligonucleotides had no significant effect on both IL-4 and IL-9 production, although mismatched DNA caused a reduction of the average IL-4 pro-
duction. (F) High GATA-3 expression in in vitro–differentiated Th2 cells. (G) To enrich for antisense-transfected Th2 cells, we used a cotransfection sys-
tem with a plasmid expressing a truncated H2-Kk molecule followed by magnetic selection of transfected cells (see Materials and Methods). As shown by
confocal laser microscopy (G, left), there was a high DNA uptake in MACS-selected cells, and quantification of FITC-positive cells showed an enrich-
ment of cells transfected with FITC-labeled antisense DNA compared with unselected cells (G, right). There was a downregulation of GATA-3 expres-
sion in MACS-selected, antisense-transfected cells compared with untreated MACS-selected T cells as shown by Western blot analysis (H, left). Such
downregulation was not observed after treatment with GATA-3 nonsense DNA and two mismatched oligonucleotides and was associated with a marked
downregulation of IL-4 production as assessed by ELISA (H, right). AS, antisense; ASGATA3, GATA-3 antisense DNA; NSGATA3, GATA-3 nonsense
DNA; NS, nonsense DNA; MM, mismatched oligonucleotides; UN, untreated cells; CN, unstimulated control. 
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differential pressure transducer (Gaeltec). In addition, airflow was
analyzed in response to various concentrations of methacholine
(MCh) (25, 50, 75, 100, 150 mg/ml for 1 min) delivered by a jet
nebulizer (Pari-Boy; Pariwerke). Finally, the concentration of
MCh that caused a 50% reduction in expiratory airflow (MCh
 
50
 
)
was determined.
In an additional series of experiments, airway responsiveness
was assessed by analyzing enhanced pause (PenH) responses of sa-
line- or OVA-treated mice in a body plethysmograph (model
PLY 3211; Buxco Electronics, Inc.) (34). Measurements of MCh
responsiveness were obtained by exposing mice for 5 min to 200
mg/ml of aerosolized MCh and monitoring PenH. Results were
 
expressed as the peak of fold-increase of PenH within 5 min after
MCh treatment.
In addition, pulmonary resistance (RL) was measured in the
same cohort of untreated and treated OVA-sensitized mice as de-
scribed previously (35, 36). In brief, dose–response curves to
MCh were obtained in anesthetized mice after administering in-
creasing doses of intravenous MCh (33–1,000 
 
 
 
g/kg). Data were
expressed as mean values of RL 
 
  
 
SEM.
 
Statistical Analysis.
 
Differences were evaluated for signifi-
cance (
 
P
 
   
 
0.05) by the Student’s two-tailed 
 
t
 
 test for in-
dependent events (Statworks). Data are given as mean val-
ues 
 
 
 
 SEM.
Figure 2. Increased number of GATA-3–producing lung cells in OVA-sensitized mice and inhibition of GATA-3 protein expression after local ad-
ministration of antisense oligonucleotides. Sections of OVA-immunized (B) and saline-treated control mice (A) were stained with an antibody against
GATA-3 (Cy3). OVA immunization caused an upregulation of GATA-3 (B) expression. Intranasal administration of GATA-3 antisense oligonucleotides
suppressed GATA-3 (C) expression in the lung of OVA-immunized mice (original magnification:  400). The same field analyzed for FITC-labeled an-
tisense DNA uptake is shown in F (FITC; emission wavelength, 520 nm). Double staining showed the absence of GATA-3 protein expression in cells
with intracellular FITC-labeled antisense DNA to GATA-3 (compare C and F). Local treatment with control oligonucleotides did not change signifi-
cantly the number of GATA-3–positive cells in the lung compared with OVA-sensibilized airways (nonsense and mismatched oligonucleotide treatment
is shown in E and D, respectively), although mismatched DNA led to a reduction in the average number of GATA-3–expressing cells per HPF (bottom
panel). In these quantitative studies, GATA-3–positive cells in OVA-immunized mice, GATA-3 antisense, mismatched, and nonsense-treated OVA-
immunized mice, and saline-treated control mice were assessed by immunohistochemistry. GATA-3–expressing cells in the lungs were quantified blindly
by the same observer (see Materials and Methods). 10 HPFs in the area of peripheral bronchi were randomly selected in nine lung sections from each
mouse (five mice per group) for quantification. Counts are given as cells per HPF. AS-GATA, GATA-3 antisense; MM-GATA, mismatched GATA-3;
NS-GATA, nonsense GATA-3; OVA, OVA-immunized mice. 
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For the analysis of RL data the multivariate analysis
MANOVA (Wilks Lambda) was used.
Results
Suppression of IL-4 but Not IL-9 Release in Th2 CD4  T
Cells by a Specific Antisense Phosphorothioate Oligonucleotide to
the Translation Start Site of GATA-3. In an attempt to
specifically downregulate expression of GATA-3 in T lym-
phocytes in vitro and in vivo, we used an antisense DNA
strategy. Accordingly, we designed specific CpG-lacking
antisense phosphorothioate oligonucleotides targeting the
translation start site of murine GATA-3 (see Materials and
Methods). Then we tested the ability of such oligonucle-
otides to specifically downregulate GATA-3 expression in
CD4  cells isolated from the spleen during Th2 cell differ-
entiation in vitro. We observed in coincubation studies an
efficient uptake of FITC-labeled antisense oligonucleotides
in cultured and already differentiated Th2 cells (day 6: 50–
70% of cells) and Jurkat cell lines ( 65% as assessed by
FACS® analysis and immunofluorescence; Fig. 1, A and B)
24 h after the treatment with antisense oligonucleotides to
GATA-3. This finding was associated with a downregula-
tion of GATA-3 expression and a significant reduction of
IL-4 release 12 h after incubation with PMA/ionomycin
(Fig. 1, C and D, respectively). However, IL-9 production
by spleen T cells remained unchanged after antisense
GATA-3 treatment (Fig. 1 E). It should be noted that the
observed 50% reduction of PMA plus ionomycin-inducible
IL-4 production upon antisense treatment is remarkable, as
only 50–70% of the spleen cells showed DNA uptake. In-
deed, cotransfection- based enrichment of antisense-trans-
fected T cells led to a more pronounced downregulation of
IL-4 production by Th2 cells (Fig. 1).
Treatment with control nonsense oligonucleotides did
not affect GATA-3 expression or IL-4 and IL-9 release un-
Figure 3. Detection of GATA-3 in the lungs of OVA-immunized
mice by gel retardation assay (EMSA) and Western blot analysis. (A) Ex-
pression of GATA-3 in cellular extracts from lung cells was assessed by
EMSA using a GATA-3–specific reference binding site. Unbound radio-
labeled probe was separated from DNA–protein complexes by gel elec-
trophoresis under nondenaturing conditions. OVA immunization led to a
strong increase of GATA-3 expression in the lung compared with lungs
from saline-treated control mice. Whereas treatment with GATA-3 anti-
sense oligonucleotides caused a suppression of GATA-3 expression, treat-
ment with GATA-3 nonsense DNA or corticosteroids had no effect on
GATA-3 expression. Specificity of the GATA-3 signal was shown by
competition assays using unlabeled GATA-3 oligonucleotides (data not
shown) and supershift assays with specific antibodies to GATA-3.
Whereas a control antibody had no effect on the GATA-3 complex in
EMSA, a complete abrogation of the retarded complex was observed
upon addition of the GATA-3–specific antibody (right). (B) Specificity of
the effects of GATA-3 antisense oligonucleotides on GATA-3 expres-
sion. The expression of GATA-3, OCT-1, and SP-1 transcription factors
in cellular extracts from lung cells was assessed by EMSA using specific
reference binding sites. Although antisense oligonucleotides to GATA-3
caused a marked reduction of GATA-3 expression, they had no such ef-
fect on the expression of OCT-1 and SP-1. The expression of GATA-3
in lung extracts was finally assessed in three independent experiments us-
ing EMSA analysis. Quantification of the EMSA bands in these three ex-
periments is depicted on the right (signal in untreated conditions was de-
fined as 100%). Whereas GATA-3 antisense DNA led to a significant
(P   0.01) reduction of GATA-3 expression, nonsense DNA had no
such effect. Mismatched DNA had no significant effect on GATA-3 ex-
pression, although a reduction in the average GATA-3 signal was noted.
**P   0.01. (C) Western blot analysis for GATA-3 and  -actin expres-
sion in the lungs of OVA-immunized mice. Extracts from lung tissue
were analyzed using a GATA-3–specific antibody. GATA-3 antisense
DNA treatment led to a suppression of GATA-3 expression, whereas
control nonsense GATA-3 oligonucleotides and corticosteroids had no
such effect. One representative out of three lungs per group is shown. 50
 g of proteins per lane was loaded. Equal loading was also confirmed after
5 min staining of the nitrocellulose membrane with Ponceau’s solution
(data not shown). AS, antisense; NS, nonsense; MM, mismatched.1253 Finotto et al.
der the same experimental conditions. Treatment with
mismatched DNA also led to a reduction of the average
number of GATA-3–expressing cells and IL-4 release, pos-
sibly due to a remaining weak hybridization of the mis-
matched DNA to the GATA-3 target mRNA (Fig. 1).
However, this effect was less pronounced compared with
the antisense DNA effect, and the mismatched DNA–
induced changes were not statistically significant. Further-
more, this effect was not seen using a second mismatched
control oligonucleotide (Fig. 1 H), suggesting that antisense
oligonucleotides to GATA-3 cause a specific suppression of
GATA-3 expression and IL-4 production by cultured T
cells.
Intranasal Administration of GATA-3 Antisense Oligonucle-
otides Decreases Lung GATA-3 Protein Expression in a Murine
Model of Asthma. Based on previous studies showing a
key role for GATA-3 in Th2 cytokine production and in-
creased Th2 cytokine production in asthma (2, 18), we an-
alyzed in a consecutive series of studies the expression of
GATA-3 in a murine model of asthma (37) associated with
late phase allergic pulmonary inflammation in OVA-sensi-
tized mice. Accordingly, we immunostained lung sections
from OVA-treated and control mice with anti–GATA-3
antibodies. As shown in Fig. 2, OVA immunization caused
a striking increase in lung-infiltrating cells expressing
GATA-3 compared with saline treatment.
In further studies, we wanted to directly test the effects
of GATA-3 antisense phosphorothioate oligonucleotides
on the expression of GATA-3 during the late phase allergic
asthmatic reaction in vivo. Intranasal delivery of FITC-
labeled GATA-3 antisense oligonucleotides led to a DNA
uptake by GATA-3–expressing lung cells in vivo (Fig. 2, C
and F). This finding was accompanied by a significant de-
crease of GATA-3 expression in the lung of OVA-sensi-
tized mice (Fig. 2, B and C, and bottom panel), while con-
trol nonsense oligonucleotides had no such effect (Fig. 2 E,
and bottom panel). Mismatched DNA led to a reduction of
the number of GATA-3- positive cells in the lung (Fig. 2
D, and bottom panel), although this effect was not statisti-
cally significant.
In additional studies, we performed Western blot analysis
of total proteins derived from the lung to assess local
GATA-3 expression. As shown in Fig. 3, these studies con-
firmed the downregulation of GATA-3 protein expression
in antisense GATA-3–treated lungs but not in lungs treated
with control nonsense oligonucleotides (Fig. 3 C). Simi-
larly, analysis of lung proteins for GATA-3 expression by
gel retardation assays (EMSA) using a GATA-3 consensus
oligonucleotide confirmed the downregulation of GATA-3
upon antisense treatment (Fig. 3 A). Densitometric analy-
sis of the EMSA bands showed a significant downregula-
tion of GATA-3 upon antisense DNA treatment (Fig. 3 B).
In contrast, the transcription factors OCT-1 and SP-1 were
not affected by GATA-3 antisense DNA (Fig. 3 B). Fur-
thermore, nonsense control oligonucleotides were virtually
inactive with regard to GATA-3 expression. Taken to-
gether, these results indicated that local administration of
Figure 4. Histologic evidence of airway inflammation in OVA-sensi-
tized and control mice; effect of GATA-3 antisense treatment. Lung tissue
was analyzed from untreated (C and D) and antisense-treated (E and F)
OVA-sensitized mice. In untreated mice, a massive peribronchial infiltra-
tion with eosinophils, thickening of the basement membrane, and deepi-
thelialization were seen (see higher magnification in D:  400). In con-
trast, after treatment with antisense DNA to GATA-3 an intact bronchial
epithelial layer and no eosinophil infiltration were seen (E and F) compa-
rable to DEX treatment (I and K). Lung tissues taken from sham (saline)-
sensitized mice (A and B) and OVA-immunized mice treated with non-
sense DNA (G and H) are shown as control. Lung sections were stained
with hematoxylin and eosin and examined by light microscopy. Original
magnifications: (A, C, E, G, and H)  200; (B, D, F, H, and K)  400.1254 Antisense DNA to GATA-3 Abrogates Airway Hyperresponsiveness
specific antisense oligonucleotides leads to specific down-
regulation of pulmonary GATA-3 expression in an asthma
model in vivo.
Inhibition of Allergen-induced Airway Inflammation by GATA-3
Antisense Oligonucleotides. To assess the histologic effects
of GATA-3 antisense phosphorothioate oligonucleotides
on allergen-induced airway inflammation, we analyzed
lung tissues 24 h after the last of three sequential OVA
challenges (days 25–27) on day 28. In untreated OVA-sen-
sitized mice, an infiltration of the bronchial interstitium
with eosinophils was observed (Fig. 4, C and D). Treat-
ment of OVA-sensitized mice with nonsense GATA-3 oli-
gonucleotides had no detectable effects (Fig. 4, G and H).
In contrast, no inflammatory signs were seen in OVA-
sensitized mice upon treatment with corticosteroids or
GATA-3 antisense oligonucleotides (Fig. 4, I, K, E, and F).
Control mice were treated with saline complexed with
alum and rechallenged intranasally with saline; they show
an intact airway epithelium and no sign of inflammation
(Fig. 4, A and B).
Antisense Oligonucleotides to GATA-3 Inhibit Infiltration of
Eosinophils in the Lung. In further studies on the potential
mechanisms of antisense-induced suppression of lung in-
flammation, we assessed allergen-induced infiltration of
eosinophils in the lung. By morphometric analysis, the in-
flux of eosinophils into the lung interstitium was signifi-
cantly reduced after administration of GATA-3 antisense
oligonucleotides compared with untreated mice (Fig. 5).
Antisense-induced suppression of the number of eosino-
phils in the BALF was comparable to that induced by intra-
nasal DEX treatment (BAL cell viability 77.5    9.8%).
However, no difference was seen in cell viability in the
Figure 5. Infiltration of eosinophils into the airways is abrogated by local administration of GATA-3 antisense oligonucleotides (significance: *P  
0.05; **P   0.01; **P   0.001). (A) Eosinophils in the BALF were detected on cytospins after staining according to May-Grünwald Giemsa and quanti-
fied after counting of 200 cells. Data are reported as the mean percentage of eosinophils in the BAL   SEM (n   4–5 animals per group). (B) Absolute
eosinophil numbers   SEM in the recovered BALF. Results were obtained by multiplying the percentage of eosinophils with the total cell number per
milliliter and the recovered volume of the BALF. (C) Three representative fields around peripheral bronchi of similar size were randomly selected from
lung sections and eosinophils were counted with a computerized system (see Materials and Methods). Data are reported as the mean number of eosino-
phils per mm2   SEM. Significant differences compared with OVA treatment are indicated. (D–F) A representative field of the BALF from a saline-
treated mouse (D) and an OVA-sensitized animal with (F) or without (E) antisense GATA-3 DNA treatment are shown. Cytospins were stained with
May-Grünwald Giemsa. AS, antisense; NS, nonsense; MM, mismatched.1255 Finotto et al.
BALF after antisense treatment in OVA-sensitized lungs
compared with saline treatment (84.4   3.5% and 91.15  
6.3% viability, respectively, as assessed by trypan blue ex-
clusion). In contrast, treatment with control mismatched
(BAL cell viability 87.27   3.8%) and nonsense oligonu-
cleotides (BAL cell viability 79.15   5.45%) had no signifi-
cant effect on the OVA-induced influx of eosinophils in
the airways (Fig. 5).
Antisense Oligonucleotides to GATA-3 Inhibit Th2 Cytokine
Production and Infiltration of Eosinophils in the Lung of OVA-
sensitized Mice. Since T cell cytokines are known to regu-
late airway inflammation in vivo, we next determined Th1
and Th2 cytokine levels in the BALF of OVA-sensitized
mice (Fig. 6). Interestingly, neither OVA nor antisense
treatment altered IFN-  levels in the BALF compared
with saline-treated mice. However, IL-4 concentration
in the BAL was significantly suppressed (P    0.05) by
GATA-3 antisense DNA treatment, suggesting that block-
ade of GATA-3 expression selectively inhibits Th2 cyto-
kine levels in the BAL. Nonsense control DNA did not
cause significant changes in IL-4 production, whereas mis-
matched oligonucleotides led to downregulation of the av-
erage IL-4 production. However, this effect was not statis-
tically significant.
Local Treatment with Antisense Oligonucleotides Decreased
Alcian Blue/PAS-positive Cells in the Airways of OVA-sensi-
tized Mice. Many mucus-producing cells (acidic sulfated
and neutral mucosubstances) were seen in the airways of
mice sensitized to OVA (Fig. 7) compared with saline-
treated mice (saline), as assessed by the alcian blue/PAS re-
action. These inflammatory changes were absent in mice
that were treated with GATA-3 antisense DNA (AS-
GATA-3). DEX treatment reduced PAS-positive cells in
the airways. In contrast, no changes were seen after treat-
ment with nonsense control oligonucleotides.
Local Treatment with Antisense Oligonucleotides to GATA-3
Suppresses Airway Hyperreactivity in OVA-sensitized Mice.
In a final series of experiments, we analyzed whether anti-
sense oligonucleotides to GATA-3 would affect airway hy-
perreactivity in OVA-sensitized mice. This point was of
particular importance since it was unclear whether modula-
tion of the function of GATA-3 would not only affect air-
way inflammation but also airway hyperresponsiveness.
In initial experiments, we subjected 12 OVA-sensitized
mice or control mice per group to treatment with antisense
oligonucleotides, control nonsense oligonucleotides, or sa-
line and assessed airway hyperreactivity by noninvasive
head-out body plethysmography after MCh challenge at day
28. As shown in Fig. 8, A and B, OVA-sensitized mice
showed an increase in airway hyperreactivity compared with
saline-treated control mice after challenge. Furthermore, it
was found that antisense oligonucleotides to GATA-3 lead
to a significant reduction of airway hyperreactivity to levels
comparable to saline-treated control mice. Finally, we ob-
served that control nonsense oligonucleotides had no effect
on airway hyperreactivity in OVA-sensitized mice.
Figure 6. GATA-3 antisense treatment selectively re-
duces Th2 cytokine concentration in the BALF. Analysis
of Th1 and Th2 cytokine concentration in the BAL from
lungs of saline-treated mice (PBS; n   4), OVA-sensitized
mice (n    4), and OVA-sensitized mice treated with
GATA-3 antisense DNA (n    5), GATA-3 nonsense
DNA (n   4), GATA-3 mismatched DNA (n   4), or
DEX (n   4). Cytokine levels (IFN- , IL-4) were deter-
mined by specific ELISA and are reported as mean val-
ues   SEM. IFN-  and IL-4 levels were between 17 and
234 pg/ml and 35 and 435 pg/ml, respectively. AS
GATA3, OVA-sensitized mice treated with GATA-3 anti-
sense DNA; MMGATA3, GATA-3 mismatched DNA;
NSGATA3, GATA-3 nonsense DNA; OVA, OVA-sensi-
tized mice.1256 Antisense DNA to GATA-3 Abrogates Airway Hyperresponsiveness
To validate our findings on a significant downregulation
of airway hyperreactivity upon antisense treatment, we as-
sessed in subsequent studies PenH responses of OVA-sensi-
tized mice in a body plethysmograph (Fig. 8 C). It was
found that administration of antisense oligonucleotides to
GATA-3 results in a significant downregulation of MCh
responsiveness, whereas nonsense control oligonucleotides
had no such effect. Finally, to assess the MCh response in
the lower airways, we measured RL and dose–response
curves to intravenous MCh in anesthetized OVA-treated
mice by body plethysmography (Fig. 8 D). These experi-
ments demonstrated a significant reduction of RL in OVA-
sensitized mice upon treatment with antisense but not
nonsense control oligonucleotides. Thus, using three inde-
pendent methods to assess airway hyperreactivity, these
data showed that airway hyperreactivity was significantly
suppressed by administration of antisense oligonucleotides
to GATA-3.
Discussion
Recent studies in transgenic mice have revealed that ex-
pression of a dominant negative form of GATA-3 can pre-
vent allergic airway inflammation (38), indicating that
GATA-3 plays a crucial role in the development of Th2-
mediated lung inflammation (39). However, it remains un-
clear whether GATA-3 plays a role in the effector phase of
allergic airway inflammation and whether antagonizing the
expression and/or function of GATA-3 can be used for the
therapy of allergic airway inflammation and hyperrespon-
siveness. Furthermore, the potential mechanisms of action of
such therapy remain to be elucidated. In this study, we dem-
onstrate a key role of the transcription factor GATA-3 for
cytokine production of T cells in the effector phase of a mu-
rine asthma model induced by OVA. We found that specific
blockade of GATA-3 expression in the lung by antisense oli-
gonucleotides leads to suppression of airway inflammation
and Th2 cytokine production both in the BAL and in the
interstitium of the lung. Antisense-induced blockade of
GATA-3 was at least as effective to suppress lung inflamma-
tion as the administration of corticosteroids. Furthermore,
using three independent methods to assess airway hyperre-
sponsiveness to MCh, we demonstrate that GATA-3 anti-
sense oligonucleotides significantly reduce airway hyperre-
sponsiveness in a model of allergic asthma, suggesting a novel
function of GATA-3 as a key regulator of airway hyperre-
sponsiveness in allergic asthma. Taken together with the re-
cently described increased expression of GATA-3 mRNA in
lung CD3  T cells of patients with allergic asthma (27), these
data suggest the potential therapeutic utility of GATA-3 an-
tisense oligonucleotides as a novel molecular approach for
the treatment of patients with allergic asthma in humans.
This approach has the potential advantage of blocking the
production of several Th2 cytokines simultaneously rather
than suppressing the activity of a single cytokine.
The GATA family of zinc finger transcription factors has
pleiotropic roles in cell development and differentiation.
Figure 7. Mucus occlusion of lower airways in OVA-treated mice
(OVA) compared with saline-treated mice (saline). The acidic and neutral
mucosubstances are stained in magenta by the alcian blue/PAS reaction.
The treatment with antisense DNA to GATA-3 (AS-GATA3) led to a
strong reduction of the PAS reaction in the airways of OVA-sensitized
mice. This effect was comparable to DEX treatment. No effect was ob-
served after nonsense DNA treatment (NS-GATA3), whereas mis-
matched DNA (MM-GATA3) led to a small reduction in mucus produc-
tion. The differences in mucus production were also assessed by
semiquantitative analysis of mucosubstances in the small and large airways
of four to five mice per group. The mean values are shown. Antisense
DNA to GATA-3 led to an abrogation of mucus production, whereas
nonsense DNA had no effects compared with OVA-sensitized untreated
mice. Mismatched DNA led to a detectable reduction in mucus produc-
tion, although this effect was much lower compared with GATA-3 anti-
sense DNA. Bottom table:  , no mucosubstances;  , mucosubstances
detectable;   , high amount of mucosubstances.1257 Finotto et al.
using an antisense DNA strategy. We found that exposure
of cultured spleen Th2 cells to an antisense GATA oligo-
nucleotide suppressed IL-4 expression. This effect on IL-4
production could be augmented by MACS-based selection
of antisense-transfected T cells using a cotransfection pro-
tocol with a plasmid expressing a truncated H2-Kk mole-
cule. In the supernatant of antisense-treated T cells, we
could not see any decrease in IL-9 production after treat-
ment with antisense to GATA-3, possibly because the IL-9
promoter has no binding sites for GATA-3 (42). Using an-
tisense oligonucleotides we then tested the potential patho-
genic role of GATA-3 in the OVA-dependent asthma
model in vivo. We observed that intranasal administration
Figure 8. Assessment of airway reactivity in BALB/c mice after GATA-3 antisense
treatment using three independent methods to assess airway hyperreactivity in vivo.
(A) 12 BALB/c mice per group were sensitized to OVA accompanied by local treat-
ment with OVA alone (PBS, OVA-sensitized mice), OVA followed by either GATA-3
antisense oligonucleotides (AS-GATA), or GATA-3 nonsense oligonucleotides
(NS-GATA). Body plethysmography was performed 24 h after the last local treatment
in all 12 mice per group as specified in Materials and Methods. Airway reactivity was
measured in nonanaesthetized, spontaneously breathing mice simultaneously during
MCh aerosol exposure. Basal values were measured (air), followed by measuring the
response to aerosolized saline (PBS) and to increasing concentrations of MCh (25–150
mg/ml). Values expressed are mean   SEM of tidal volume (%). (B) Analysis of the
MCh concentration that caused a 50% reduction in expiratory airflow (MCh50; refer-
ence 33) in the plethysmography experiments described in A. Data represent mean
values   SEM. *P   0.05. (C) Airway responsiveness in OVA- and saline-treated
mice was assessed by analyzing PenH responses in a body plethysmograph. Mice were
treated with saline (n   8) or sensitized to OVA followed by local treatment with
OVA alone (OVA; n   10), GATA-3 antisense oligonucleotides (AS-GATA; n   11)
or GATA-3 nonsense oligonucleotides (NS-GATA; n   10), as described above.
Measurements of MCh responsiveness were made after exposure for 5 min to 200 mg/
ml of aerosolized MCh and monitoring PenH. Results are expressed as the mean peak
of PenH within 5 min after MCh treatment   SEM. Data were pooled from two in-
dependent experiments. Whereas treatment with antisense oligonucleotides to
GATA-3 caused a significant reduction of PenH values (P   0.01), treatment with
nonsense control DNA did not have a significant effect. Furthermore, treatment of
OVA-sensitized mice with antisense DNA led to a significant reduction of PenH val-
ues (P   0.01) compared with nonsense, control-treated mice. (D) Analysis of RL in
anesthetized, OVA-, or saline-treated mice by body plethysmography. Mice were
treated with saline (n   8) or sensitized to OVA followed by local treatment with
OVA alone (OVA/OVA; n   11), GATA-3 antisense oligonucleotides (OVA/AS;
n   11), or GATA-3-nonsense oligonucleotides (OVA/NS; n   12). Body plethys-
mography was performed 24 h after the last local treatment in all mice. Dose–response
curves to MCh were obtained after administering indicated doses of intravenous MCh.
Data were pooled from two independent experiments and are expressed as mean val-
ues of RL   SEM. Multivariate analysis showed a significant increase of RL after
OVA treatment compared with saline treatment (P   0.05). Treatment with antisense
oligonucleotides to GATA-3 led to a significant suppression of RL values compared with untreated, OVA-sensitized mice (P   0.01), whereas nonsense
control DNA did not have a significant effect. Furthermore, treatment of OVA-sensitized mice with antisense DNA caused a significant suppression of
RL values compared with nonsense-treated, OVA-sensitized mice (P   0.05).
While GATA-1 and GATA-2 are involved in the develop-
ment of the erythroid and megakaryocytic lineages,
GATA-3 is highly expressed in early T lymphocytes and
controls T cell receptor gene expression and thymocyte de-
velopment (17, 14). Furthermore, within mature T cells
GATA-3 was found to be selectively expressed in naive T
cells and to control Th2 T cell development (18, 21, 40,
41). These data prompted us to determine the expression
and functional role of GATA-3 in a murine model of
asthma associated with Th2 cytokine production. We ob-
served that OVA sensitization of mice caused a strong up-
regulation of pulmonary GATA-3 expression. This finding
led us to further investigate the functional role of this factor1258 Antisense DNA to GATA-3 Abrogates Airway Hyperresponsiveness
of FITC-labeled GATA-3 antisense phosphorothioate oli-
gonucleotides causes an efficient uptake in interstitial lung
cells that coexpress large amounts of GATA-3 and IL-4
upon OVA sensitization. This uptake was followed by
downregulation of lung GATA-3 expression (compared
with OVA-sensitized mice without treatment) within 24 h
after the last antisense administration. The specificity of the
antisense effect on GATA-3 expression was confirmed ac-
cording to several previously described criteria (43, 44): (a)
control nonsense oligonucleotides did not have an effect on
GATA-3 expression; (b) the antisense oligonucleotide had
no effect on a nontargeted protein (SP-1, OCT-1); and (c)
direct toxic effects of the GATA-3 antisense oligonucle-
otide were excluded by cell viability tests. Interestingly,
mismatched control DNA led to a reduction of GATA-3
expression and IL-4 production in T cells, probably due to
a remaining weak hybridization of the mismatched DNA
to the GATA-3 target mRNA. However, these changes
were less pronounced compared with the antisense DNA
effect and did not reach statistical significance.
The antisense-induced suppression of GATA-3 expres-
sion was accompanied by a suppression of Th2 cytokine
synthesis in vitro and in vivo and the accumulation of eo-
sinophils in the airways, whereas treatment with control
nonsense oligonucleotides had no such effects. Mucus oc-
clusion of the airway lumen in the OVA-treated mice was
present 24 h after the last intravenous OVA administration
on day 28. Furthermore, in vivo noninvasive pulmonary
function tests using body plethysmography showed that the
OVA-immunized challenged mice reproducibly developed
increased airway responsiveness to MCh that could be
completely reversed by treatment with antisense DNA to
GATA-3 but not by control nonsense DNA. This is an im-
portant novel information that highlights GATA-3 as a key
regulator of both T cell effector function and airway hyper-
responsiveness in allergic airway inflammation. It should be
noted that the above finding on antisense-induced suppres-
sion of airway hyperresponsiveness was validated by two
additional independent methods using assessment of PenH
responses and of RL in anesthetized mice. All three meth-
ods demonstrated a significant downregulation of OVA-
induced airway hyperresponsiveness upon administration of
antisense oligonucleotides to GATA-3, definitively dem-
onstrating for the first time a critical regulatory role of
GATA-3 in airway hyperresponsiveness in allergic asthma.
The potential relevance of this GATA-3 antisense-based
approach to inhibit Th2 cytokine production is underlined
by various functional studies showing a key regulatory role
for both IL-4 and IL-5 in asthma. For instance, studies in
transgenic and knockout mice showed that the Th2 cyto-
kine IL-4 is important for IgE mRNA production in allergic
asthmatic reactions (45, 46). Furthermore, studies in a
knockout model for the IL-4–dependent STAT-6 have
shown that suppression of IL-4 signal transduction pro-
foundly inhibits influx of eosinophils into the lung (47). Fi-
nally, suppression of IL-5 has been shown to prevent allergic
inflammation in an animal model (48), possibly due to sup-
pression of IL-5–dependent activation of eosinophils (49).
Recent in vitro and in vivo studies have shown that var-
ious transcription factors such as c-maf, nuclear factor of
activated T cells c1-4, NIP 45, STAT-6, and GATA-3 are
important for Th2-type cytokine production in T cells (14,
50). Here, we show that local GATA-3 antisense DNA
treatment directly affects Th2 cytokine production and
lung inflammation in asthma, although the oligonucle-
otides lack CpG motifs. These data support and signifi-
cantly extend data from a very recent report (38) showing
that expression of a dominant negative mutant of GATA-3
in T cells from transgenic mice leads to profound attenua-
tion of OVA-induced eosinophilia and Th2 cytokine pro-
duction. However, we demonstrate in this study for the
first time that GATA-3 plays a role in the effector phase of
allergic airway inflammation using mice with a normal im-
mune system. Furthermore, we show that blockade of
GATA-3 expression can be used as a therapeutic approach
to suppress lung inflammation and mucus production in a
murine model of asthma in vivo. Finally, we have found
that GATA-3 is a critical factor for the maintenance of air-
way hyperresponsiveness in allergic airway inflammation.
Taken together, these data suggest that antisense DNA
treatment to GATA-3 is a novel selective way to simulta-
neously suppress the production of several Th2 type cyto-
kines in asthmatic reactions in vivo. Furthermore, we have
demonstrated here that GATA-3 antisense DNA treatment
of asthma is at least as effective as corticosteroid treatment,
suggesting that antisense oligonucleotides to GATA-3 may
be a novel molecular approach for the treatment of inflam-
matory disorders such as asthma in humans.
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